PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsBivalirudin
Angiomax, Angiox(bivalirudin)
Angiomax, Angiox (bivalirudin) is a protein pharmaceutical. Bivalirudin was first approved as Angiomax on 2000-12-15. It is used to treat unstable angina in the USA. It has been approved in Europe to treat acute coronary syndrome. The pharmaceutical is active against prothrombin.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Angiomax, Bivalirudin (discontinued: Bivalirudin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Bivalirudin
Tradename
Company
Number
Date
Products
ANGIOMAX RTUMAIA BiotechnologyN-211215 RX2019-07-25
1 products, RLD, RS
ANGIOMAXSandozN-020873 RX2000-12-15
1 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
angiomaxNew Drug Application2019-06-30
bivalirudinANDA2024-12-23
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
unstable anginaEFO_1000985D000789I20.0
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Bivalirudin, Angiomax Rtu, Maia Pharms Inc
119039932039-05-20U-3817
119186222039-05-20U-3817
Bivalirudin, Angiomax, Sandoz
75827272028-07-27DP
75983432028-07-27DP
ATC Codes
B: Blood and blood forming organ drugs
— B01: Antithrombotic agents
— B01A: Antithrombotic agents
— B01AE: Direct thrombin inhibitors
— B01AE06: Bivalirudin
HCPCS
Code
Description
J0583
Injection, bivalirudin, 1 mg
Clinical
Clinical Trials
89 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ThrombosisD013927———121—4
SyndromeD013577————1113
ThrombocytopeniaD013921HP_0001873D69.6——21—3
Coronary artery diseaseD003324—I25.1———112
Coronary diseaseD003327—————1—1
Myocardial ischemiaD017202EFO_1001375I20-I25———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myocardial infarctionD009203EFO_0000612I21——4——4
InfarctionD007238EFO_0009463———4——4
Coronary artery bypassD001026EFO_0003776———4——4
Acute coronary syndromeD054058EFO_0005672———2—13
Cardiovascular diseasesD002318EFO_0000319I98——2——2
Unstable anginaD000789EFO_1000985I20.0——1——1
Acute diseaseD000208————1——1
Inferior wall myocardial infarctionD056989EFO_1000983———1——1
HemorrhageD006470MP_0001914R58——1——1
Endovascular proceduresD057510————1——1
Show 4 more
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Stable anginaD060050—I20.89————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameBivalirudin
INNbivalirudin
Description
Bivalirudin is a synthetic peptide of 20 amino acids, comprising D-Phe, Pro, Arg, Pro, Gly, Gly, Gly, Gly, Asn, Gly, Asp, Phe, Glu, Glu, Ile, Pro, Glu, Glu, Tyr, and Leu in sequence. A congener of hirudin (a naturally occurring drug found in the saliva of the medicinal leech), it a specific and reversible inhibitor of thrombin, and is used as an anticoagulant. It has a role as an anticoagulant and an EC 3.4.21.5 (thrombin) inhibitor.
Classification
Protein
Drug classanticoagulants (hirudin type)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)O
Identifiers
PDB—
CAS-ID128270-60-0
RxCUI—
ChEMBL IDCHEMBL2103749
ChEBI ID59173
PubChem CID16129704
DrugBankDB00006
UNII IDTN9BEX005G (ChemIDplus, GSRS)
Target
Agency Approved
F2
F2
Organism
Homo sapiens
Gene name
F2
Gene synonyms
NCBI Gene ID
Protein name
prothrombin
Protein synonyms
Coagulation factor II, prepro-coagulation factor II, prothrombin B-chain, thrombin factor II
Uniprot ID
Mouse ortholog
F2 (14061)
prothrombin (P19221)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Bivalirudin – The Medicines Company
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 3,973 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
2,576 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use